Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848783 · ClinicalTrials.gov registry record · Phase 2
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00848783 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 8 participants.
The verdict
NCT00848783, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Irinotecan
- PROCEDURE Surgery
- DRUG Floxuridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848783
The ClinicalTrials.gov registry entry for NCT00848783 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT00848783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00848783 about?
NCT00848783 is a clinical study titled "Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers". This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
What is the current status of trial NCT00848783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00848783?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Irinotecan (DRUG), Surgery (PROCEDURE), Floxuridine (DRUG).
Who is sponsoring clinical trial NCT00848783?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.